Press Releases

;

Job Announcement: Government Affairs Manager

Jul 1, 2024

The HIV+Hepatitis Policy Institute is a national 501(c)(3) non-profit organization incorporated in the District of Columbia whose mission is to promote quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions. We are seeking a Government Affairs Manager to advocate for our policy goals to end the HIV and hepatitis epidemics and increase access and affordability of healthcare with a focus on prescription drugs.

read more

House proposes to gut ending HIV programs—again

Jun 26, 2024

“Instead of providing new investments in ending HIV by increasing funding for testing, prevention programs, such as PrEP, and life-saving care and treatment, House Republicans are again choosing to go through a worthless exercise of cutting programs that the American people depend on and will never pass,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. “These were purposeful decisions that are well below the agreed-upon budget caps. While we will vigorously fight these cuts, we look forward to working with the entire Congress in a bipartisan fashion on spending bills that can actually become law.”

read more

New CDC HIV Data Demonstrates the Impact of Flat Funding

May 21, 2024

While we would have liked to see improved outcomes, federal funding for CDC HIV prevention and the Ryan White HIV/AIDS care and treatment program, along with other critical programs, has remained flat for years. The only increases have been for the Ending the HIV Epidemic initiative, and even that program hasn’t received the increases it needs to be successful,” commented Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. “Without significant increases for care and treatment, and prevention programs, including those for PrEP, sadly we will continue to experience only small drops in the number of new diagnoses, and racial and ethnic disparities will persist. As a nation, we can and must do better.”

read more

Biden administration strengthens patient protections in accessing prescription drugs

Apr 26, 2024

“We applaud the Biden administration’s strengthening of the nondiscrimination regulation in order to ensure that patients, particularly those who rely on prescription drugs, are better protected against the discriminatory practices of some insurers and PBMs,” commented Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. “Patients are being faced with high cost-sharing, excessive utilization management techniques, such as prior authorization, drug exclusions, and now even AI tools that decide what drugs they can receive. We can now be assured that, thanks to the ACA, they must be implemented in a nondiscriminatory manner.”

read more

Federal Government Refuses to Enforce Copay Assistance Court Victory, But Moves to Stop Scheme of Classifying Drugs as “Non-Essential Health Benefits”

Apr 2, 2024

“This is nonsense: everyone agrees that patients are having trouble affording their prescription drugs, that copay assistance is helping them, and that the plans are pocketing copay assistance without crediting patients, and even though the rule that allowed insurers not to count that assistance has been struck down, our federal government openly refuses to enforce the court ruling,” commented Carl Schmid, executive director of the HIV+Hepatitis Policy Institute.

read more

Search

Press Release Tags

ACA Appropriations Biden administration CDC Congress Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B Hepatitis C hepatits HIV HIV Prevention hous housing insurer Insurers LGBT Medicaid Medicare Part D NAIC NIH PBMs PrEP Prescription Drugs prevention Private Insurance Ryan White Ryan White Program state Syringe services Testing transparency Treatment Trump administration

Recent Press Releases

Pin It on Pinterest